Skip to main
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is expected to experience some headwinds due to changes in FDA device classifications, which may result in pricing pressure and market share decline. However, the company has a diversified portfolio and has outperformed the market in multiple categories, making it a Buy with a target price of $41. With future growth expected in the global orthopedic market, Enovis's strategic acquisitions and focus on reducing debt make it a strong contender in the industry.

Bears say

Enovis is a medical technology company with a majority of its revenue coming from the Prevention & Recovery segment. Despite consistently delivering above-market growth and expanding into new product offerings, Enovis's shares are currently trading at a discount to its peers, which we believe is unwarranted. We expect Enovis to continue generating strong growth, optimizing its portfolio, and improving its financials, which should support an increase in its valuation multiple. While there are risks of competition, seasonality, and existing debt, we see Enovis as an attractive value asset with potential for steady performance and share returns.

Enovis Corp (ENOV) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.